In cervical cancer, a combined determination of the markers ALDH, OCT4, and NANOG is recommended; the activity of ALDHA1 and OCT4 is increased in the tissues of cervical cancer and precancerous lesions, as well as in the blood plasma [59]. This evidence concerns the gene POU5F1 and cervical carcinoma.